Recent Updates — CLGN

On October 14, 2026, CollPlant Biotechnologies Ltd closed a private placement offering with institutional investors, raising approximately $3.7 million in gross proceeds. The company issued 989,301 ordinary shares and pre-funded warrants at a combined price of $3.74 per share and accompanying warrant. Investors also received unregistered ordinary warrants to purchase up to 1,483,950 additional shares with an exercise price of $3.74, exercisable immediately and expiring five years after the effective date of a registration statement. The company intends to use the net proceeds for general corporate purposes, including working capital and funding research and development programs. CollPlant Biotechnologies Ltd operates in the biotechnology industry, focusing on plant-based collagen production.

CollPlant Biotechnologies announced a $3.7 million private placement of 989,301 ordinary shares and warrants exercisable for up to 1,483,952 additional shares. The securities were sold at $3.74 per share to existing investors, with closing expected around October 14, 2026. Proceeds will primarily accelerate research and development for subsidiary LightSolver's laser-based supercomputing architecture and support general corporate purposes. CollPlant operates in deep-tech photonic computing and advanced biotechnology.

CollPlant Biotechnologies Ltd. completed its acquisition of LightSolver Ltd., an Israeli developer of photonic computing technology, on September 3, 2026. The transaction diversifies CollPlant's portfolio into high-performance computing alongside its existing regenerative medicine business. Concurrently, the company reported second quarter 2026 financial results showing GAAP revenues of $108,000 and a net loss of $2.7 million. Cash and cash equivalents stood at $2.6 million as of June 30, 2026. CollPlant operates in biotechnology and deep-tech computing.